Open an Account
search icon
3
NOTIFICATIONS
Best Algo trading app in India
Bigul

Announces Q2 results (Standalone & Consolidated), Results Press Release, Presentation & Limited Review Report (Standalone & Consolidated) for the Quarter ended September 30, 2016

 Jubilant Life Sciences Ltd has announced the following results for the quarter ended September 30, 2016:The Unaudited Standalone results for the Quarter ended September 30, 2016The Company has posted a net profit of Rs. 241.20 million for the quarter ended September 30, 2016 as compared to Rs. 516.10 million for the quarter ended September 30, 2015. Total Income has decreased from Rs. 7840.30 million for the quarter ended September...
27-10-2016
Bigul

Board Meeting on Oct 27, 2016

 Jubilant Life Sciences Ltd has informed BSE that the Board of Directors of the Company shall, at its meeting scheduled to be held on October 27, 2016, inter alia, consider the proposal to issue Non-Convertible Debentures up to an amount of Rs. 1,000 crore.
24-10-2016
Bigul

Shareholding for the Period Ended September 30, 2016

 Jubilant Life Sciences Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2016. For more details, kindly Click here
19-10-2016
Bigul

Today's Pick: Jubilant Life Sciences (English) by Lavanya Prabhakaran
18-10-2016
Bigul

Schedule of Investor Conference Call

 Jubilant Life Sciences Ltd has informed BSE regarding "Schedule of Investor Conference Call for Jubilant Life Sciences Limited - Unaudited Financial Results for the quarter ended September 30, 2016".
18-10-2016
Bigul

Q2 results on Oct 27, 2016

 Jubilant Life Sciences Ltd has informed BSE that a meeting of the Board of Directors of the Company is scheduled to be held on October 27, 2016, inter alia, to consider Unaudited Financial Results of the Company for the quarter ended September 30, 2016 (Q2).Further, as per the Companys Code of Conduct for Prevention of Insider Trading, the Trading Window for dealing in the securities of the Company would remain closed for the Designated...
18-10-2016
Bigul

Jubilant Life raises Rs 50 cr by issue of commercial papers

 Drug firm Jubilant Life Sciences today said it has raised Rs 50 crore through issuing commercial papers. The company has issued commercial papers for an aggregate amount of Rs 50 crore on...
14-10-2016
Bigul

Issuance of Commercial Paper of an aggregate amount of Rs. 50 crore

 Jubilant Life Sciences Ltd has informed BSE that the Company has issued Commercial Papers for an aggregate amount of Rs. 50 crore on October 14, 2016, having maturity date of December 20, 2016, which have been rated IND A1+ by India Ratings & Research Private Limited.The aggregate amount of Commercial Papers outstanding as on date is Rs. 50 crore.
14-10-2016
Bigul

Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 for Quarter ended September 30, 2016

 Jubilant Life Sciences Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended September 30, 2016, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
14-10-2016
Bigul

Jubilant Life gets USFDA nod for urinary incontinence drug

 Jubilant Life Sciences has received the final approval from the US health regulator for Darifenacin Extended-Release Tablets, used for the treatment of urinary incontinence. The company has...
13-10-2016
Next Page
Close

Let's Open Free Demat Account